Cell counts and frequencies of cellular subsets in peripheral blood in the patient and controls
Cell counts (normal range) and frequencies (%) . | IgG4-RSM . | HD . | GPA . | ||
---|---|---|---|---|---|
Baseline . | Week 6 . | Week 12 . | |||
Neutrophil cell count (1500–7700/µl) | 7990 | 8740 | 7810 | 5130 | 3930 |
% of SLAMF7+ neutrophils | 61 | 16 | 10 | 10 | 54 |
SLAMF7+ neutrophil cell count/µl | 4874 | 1404 | 781 | 513 | 2122 |
Monocyte cell count (100–1000/µl) | 900 | 1230 | 860 | 780 | 980 |
% of SLAMF7+ monocytes | 86 | 43 | 49 | 38 | 73 |
SLAMF7+ monocyte cell count/µl | 774 | 529 | 421 | 296 | 715 |
Lymphocyte cell count (1100–4000/µl) | 1280 | 1560 | 1230 | 2890 | 1900 |
% of SLAMF7+ lymphocytes | 36 | 60 | 78 | 35 | 10 |
SLAMF7+ lymphocyte cell count/µl | 461 | 936 | 959 | 1011 | 190 |
CD3+ T cell count (700–2100/µl) | 1.097 | 995 | 1174 | 863 | 1177 |
% of SLAMF7+ cells within CD3+ T cell population | 65 | 69 | 81 | 24 | 4 |
CD3+SLAMF7+ cell count/µl | 713 | 687 | 950 | 207 | 47 |
CD4+ T cell count (300–1400/µl) | 714 | 697 | 815 | 649 | 472 |
% of SLAMF7+ cells within CD4+ T cell population | 47 | 30 | 63 | 4 | 22 |
CD4+SLAMF7+ cell count/µl | 336 | 209 | 513 | 26 | 104 |
% of CD28+ cells within CD4+ T cell population | 71 | 89 | 59 | 97 | 87 |
% of CD27– cells within CD4+CD28+ T cell population | 23 | 23 | 36 | 4 | 9 |
% of SLAMF7+ cells within CD4+CD28+ T cell population | 24 | 21 | 40 | 4 | 13 |
% of CD28– cells within CD4+ T cell population | 29 | 11 | 41 | 3 | 13 |
% of CD27– cells within CD4+CD28– T cell population | 99 | 99 | 99 | 5 | 96 |
% of SLAMF7+ cells within CD4+CD28– T cell population | 99 | 91 | 96 | 13 | 91 |
CD8+ T cell cell count (200–900/µl) | 391 | 329 | 399 | 216 | 683 |
% of SLAMF7+ cells within CD8+ T cell population | 96 | 96 | 98 | 65 | 92 |
CD8+SLAMF7+ cell count/µl | 375 | 315 | 391 | 140 | 638 |
% of CD28+ cells within CD8+ T cell population | 27 | 33 | 21 | 86 | 15 |
% of CD27– cells within CD8+CD28+ T cell population | 14 | 18 | 20 | 5 | 11 |
% of SLAMF7+ cells within CD8+CD28+ T cell population | 82 | 89 | 94 | 60 | 47 |
% of CD28– cells within CD8+ T cell population | 73 | 67 | 79 | 14 | 85 |
% of CD27– cells within CD8+CD28– T cell population | 86 | 83 | 83 | 40 | 91 |
% of SLAMF7+ cells within CD8+CD28– T cell population | 100 | 99 | 98 | 96 | 99 |
% of CD4+CD8+ DP cells within CD3+ T cell population | 6 | 23 | 13 | 1 | 2 |
% of SLAMF7+ cells within CD4+CD8+ DP T cell population | 98 | 99 | 99 | 22 | 70 |
% of CD56+ cells within CD3+ T cell population | 19 | 26 | 30 | 5 | 18 |
% of SLAMF7+ cells within CD3+CD56+ NKT cell population | 99 | 99 | 99 | 97 | 99 |
CD3+CD56+SLAMF7+ cell count/µl | 206 | 256 | 350 | 40 | 209 |
CD19+ B cell cell count (100–500/µl) | 7 | 8 | 10 | 128 | 1 |
CD3-CD56+ NK cells cell count (90–600/µl) | 101 | 57 | 97 | 150 | 156 |
% of CD56+ cells within CD3– cell population | 8 | 31 | 59 | 52 | 50 |
% of SLAMF7+ cells within CD3–CD56+ NK cell population | 98 | 99 | 98 | 98 | 99 |
CD3–CD56+SLAMF7+ cell count/µl | 7 | 16 | 56 | 77 | 76 |
Cell counts (normal range) and frequencies (%) . | IgG4-RSM . | HD . | GPA . | ||
---|---|---|---|---|---|
Baseline . | Week 6 . | Week 12 . | |||
Neutrophil cell count (1500–7700/µl) | 7990 | 8740 | 7810 | 5130 | 3930 |
% of SLAMF7+ neutrophils | 61 | 16 | 10 | 10 | 54 |
SLAMF7+ neutrophil cell count/µl | 4874 | 1404 | 781 | 513 | 2122 |
Monocyte cell count (100–1000/µl) | 900 | 1230 | 860 | 780 | 980 |
% of SLAMF7+ monocytes | 86 | 43 | 49 | 38 | 73 |
SLAMF7+ monocyte cell count/µl | 774 | 529 | 421 | 296 | 715 |
Lymphocyte cell count (1100–4000/µl) | 1280 | 1560 | 1230 | 2890 | 1900 |
% of SLAMF7+ lymphocytes | 36 | 60 | 78 | 35 | 10 |
SLAMF7+ lymphocyte cell count/µl | 461 | 936 | 959 | 1011 | 190 |
CD3+ T cell count (700–2100/µl) | 1.097 | 995 | 1174 | 863 | 1177 |
% of SLAMF7+ cells within CD3+ T cell population | 65 | 69 | 81 | 24 | 4 |
CD3+SLAMF7+ cell count/µl | 713 | 687 | 950 | 207 | 47 |
CD4+ T cell count (300–1400/µl) | 714 | 697 | 815 | 649 | 472 |
% of SLAMF7+ cells within CD4+ T cell population | 47 | 30 | 63 | 4 | 22 |
CD4+SLAMF7+ cell count/µl | 336 | 209 | 513 | 26 | 104 |
% of CD28+ cells within CD4+ T cell population | 71 | 89 | 59 | 97 | 87 |
% of CD27– cells within CD4+CD28+ T cell population | 23 | 23 | 36 | 4 | 9 |
% of SLAMF7+ cells within CD4+CD28+ T cell population | 24 | 21 | 40 | 4 | 13 |
% of CD28– cells within CD4+ T cell population | 29 | 11 | 41 | 3 | 13 |
% of CD27– cells within CD4+CD28– T cell population | 99 | 99 | 99 | 5 | 96 |
% of SLAMF7+ cells within CD4+CD28– T cell population | 99 | 91 | 96 | 13 | 91 |
CD8+ T cell cell count (200–900/µl) | 391 | 329 | 399 | 216 | 683 |
% of SLAMF7+ cells within CD8+ T cell population | 96 | 96 | 98 | 65 | 92 |
CD8+SLAMF7+ cell count/µl | 375 | 315 | 391 | 140 | 638 |
% of CD28+ cells within CD8+ T cell population | 27 | 33 | 21 | 86 | 15 |
% of CD27– cells within CD8+CD28+ T cell population | 14 | 18 | 20 | 5 | 11 |
% of SLAMF7+ cells within CD8+CD28+ T cell population | 82 | 89 | 94 | 60 | 47 |
% of CD28– cells within CD8+ T cell population | 73 | 67 | 79 | 14 | 85 |
% of CD27– cells within CD8+CD28– T cell population | 86 | 83 | 83 | 40 | 91 |
% of SLAMF7+ cells within CD8+CD28– T cell population | 100 | 99 | 98 | 96 | 99 |
% of CD4+CD8+ DP cells within CD3+ T cell population | 6 | 23 | 13 | 1 | 2 |
% of SLAMF7+ cells within CD4+CD8+ DP T cell population | 98 | 99 | 99 | 22 | 70 |
% of CD56+ cells within CD3+ T cell population | 19 | 26 | 30 | 5 | 18 |
% of SLAMF7+ cells within CD3+CD56+ NKT cell population | 99 | 99 | 99 | 97 | 99 |
CD3+CD56+SLAMF7+ cell count/µl | 206 | 256 | 350 | 40 | 209 |
CD19+ B cell cell count (100–500/µl) | 7 | 8 | 10 | 128 | 1 |
CD3-CD56+ NK cells cell count (90–600/µl) | 101 | 57 | 97 | 150 | 156 |
% of CD56+ cells within CD3– cell population | 8 | 31 | 59 | 52 | 50 |
% of SLAMF7+ cells within CD3–CD56+ NK cell population | 98 | 99 | 98 | 98 | 99 |
CD3–CD56+SLAMF7+ cell count/µl | 7 | 16 | 56 | 77 | 76 |
IgG4-RSM: IgG4-related sclerosing mesenteritis; GPA: granulomatosis with polyangiitis; HD: healthy donor.
Cell counts and frequencies of cellular subsets in peripheral blood in the patient and controls
Cell counts (normal range) and frequencies (%) . | IgG4-RSM . | HD . | GPA . | ||
---|---|---|---|---|---|
Baseline . | Week 6 . | Week 12 . | |||
Neutrophil cell count (1500–7700/µl) | 7990 | 8740 | 7810 | 5130 | 3930 |
% of SLAMF7+ neutrophils | 61 | 16 | 10 | 10 | 54 |
SLAMF7+ neutrophil cell count/µl | 4874 | 1404 | 781 | 513 | 2122 |
Monocyte cell count (100–1000/µl) | 900 | 1230 | 860 | 780 | 980 |
% of SLAMF7+ monocytes | 86 | 43 | 49 | 38 | 73 |
SLAMF7+ monocyte cell count/µl | 774 | 529 | 421 | 296 | 715 |
Lymphocyte cell count (1100–4000/µl) | 1280 | 1560 | 1230 | 2890 | 1900 |
% of SLAMF7+ lymphocytes | 36 | 60 | 78 | 35 | 10 |
SLAMF7+ lymphocyte cell count/µl | 461 | 936 | 959 | 1011 | 190 |
CD3+ T cell count (700–2100/µl) | 1.097 | 995 | 1174 | 863 | 1177 |
% of SLAMF7+ cells within CD3+ T cell population | 65 | 69 | 81 | 24 | 4 |
CD3+SLAMF7+ cell count/µl | 713 | 687 | 950 | 207 | 47 |
CD4+ T cell count (300–1400/µl) | 714 | 697 | 815 | 649 | 472 |
% of SLAMF7+ cells within CD4+ T cell population | 47 | 30 | 63 | 4 | 22 |
CD4+SLAMF7+ cell count/µl | 336 | 209 | 513 | 26 | 104 |
% of CD28+ cells within CD4+ T cell population | 71 | 89 | 59 | 97 | 87 |
% of CD27– cells within CD4+CD28+ T cell population | 23 | 23 | 36 | 4 | 9 |
% of SLAMF7+ cells within CD4+CD28+ T cell population | 24 | 21 | 40 | 4 | 13 |
% of CD28– cells within CD4+ T cell population | 29 | 11 | 41 | 3 | 13 |
% of CD27– cells within CD4+CD28– T cell population | 99 | 99 | 99 | 5 | 96 |
% of SLAMF7+ cells within CD4+CD28– T cell population | 99 | 91 | 96 | 13 | 91 |
CD8+ T cell cell count (200–900/µl) | 391 | 329 | 399 | 216 | 683 |
% of SLAMF7+ cells within CD8+ T cell population | 96 | 96 | 98 | 65 | 92 |
CD8+SLAMF7+ cell count/µl | 375 | 315 | 391 | 140 | 638 |
% of CD28+ cells within CD8+ T cell population | 27 | 33 | 21 | 86 | 15 |
% of CD27– cells within CD8+CD28+ T cell population | 14 | 18 | 20 | 5 | 11 |
% of SLAMF7+ cells within CD8+CD28+ T cell population | 82 | 89 | 94 | 60 | 47 |
% of CD28– cells within CD8+ T cell population | 73 | 67 | 79 | 14 | 85 |
% of CD27– cells within CD8+CD28– T cell population | 86 | 83 | 83 | 40 | 91 |
% of SLAMF7+ cells within CD8+CD28– T cell population | 100 | 99 | 98 | 96 | 99 |
% of CD4+CD8+ DP cells within CD3+ T cell population | 6 | 23 | 13 | 1 | 2 |
% of SLAMF7+ cells within CD4+CD8+ DP T cell population | 98 | 99 | 99 | 22 | 70 |
% of CD56+ cells within CD3+ T cell population | 19 | 26 | 30 | 5 | 18 |
% of SLAMF7+ cells within CD3+CD56+ NKT cell population | 99 | 99 | 99 | 97 | 99 |
CD3+CD56+SLAMF7+ cell count/µl | 206 | 256 | 350 | 40 | 209 |
CD19+ B cell cell count (100–500/µl) | 7 | 8 | 10 | 128 | 1 |
CD3-CD56+ NK cells cell count (90–600/µl) | 101 | 57 | 97 | 150 | 156 |
% of CD56+ cells within CD3– cell population | 8 | 31 | 59 | 52 | 50 |
% of SLAMF7+ cells within CD3–CD56+ NK cell population | 98 | 99 | 98 | 98 | 99 |
CD3–CD56+SLAMF7+ cell count/µl | 7 | 16 | 56 | 77 | 76 |
Cell counts (normal range) and frequencies (%) . | IgG4-RSM . | HD . | GPA . | ||
---|---|---|---|---|---|
Baseline . | Week 6 . | Week 12 . | |||
Neutrophil cell count (1500–7700/µl) | 7990 | 8740 | 7810 | 5130 | 3930 |
% of SLAMF7+ neutrophils | 61 | 16 | 10 | 10 | 54 |
SLAMF7+ neutrophil cell count/µl | 4874 | 1404 | 781 | 513 | 2122 |
Monocyte cell count (100–1000/µl) | 900 | 1230 | 860 | 780 | 980 |
% of SLAMF7+ monocytes | 86 | 43 | 49 | 38 | 73 |
SLAMF7+ monocyte cell count/µl | 774 | 529 | 421 | 296 | 715 |
Lymphocyte cell count (1100–4000/µl) | 1280 | 1560 | 1230 | 2890 | 1900 |
% of SLAMF7+ lymphocytes | 36 | 60 | 78 | 35 | 10 |
SLAMF7+ lymphocyte cell count/µl | 461 | 936 | 959 | 1011 | 190 |
CD3+ T cell count (700–2100/µl) | 1.097 | 995 | 1174 | 863 | 1177 |
% of SLAMF7+ cells within CD3+ T cell population | 65 | 69 | 81 | 24 | 4 |
CD3+SLAMF7+ cell count/µl | 713 | 687 | 950 | 207 | 47 |
CD4+ T cell count (300–1400/µl) | 714 | 697 | 815 | 649 | 472 |
% of SLAMF7+ cells within CD4+ T cell population | 47 | 30 | 63 | 4 | 22 |
CD4+SLAMF7+ cell count/µl | 336 | 209 | 513 | 26 | 104 |
% of CD28+ cells within CD4+ T cell population | 71 | 89 | 59 | 97 | 87 |
% of CD27– cells within CD4+CD28+ T cell population | 23 | 23 | 36 | 4 | 9 |
% of SLAMF7+ cells within CD4+CD28+ T cell population | 24 | 21 | 40 | 4 | 13 |
% of CD28– cells within CD4+ T cell population | 29 | 11 | 41 | 3 | 13 |
% of CD27– cells within CD4+CD28– T cell population | 99 | 99 | 99 | 5 | 96 |
% of SLAMF7+ cells within CD4+CD28– T cell population | 99 | 91 | 96 | 13 | 91 |
CD8+ T cell cell count (200–900/µl) | 391 | 329 | 399 | 216 | 683 |
% of SLAMF7+ cells within CD8+ T cell population | 96 | 96 | 98 | 65 | 92 |
CD8+SLAMF7+ cell count/µl | 375 | 315 | 391 | 140 | 638 |
% of CD28+ cells within CD8+ T cell population | 27 | 33 | 21 | 86 | 15 |
% of CD27– cells within CD8+CD28+ T cell population | 14 | 18 | 20 | 5 | 11 |
% of SLAMF7+ cells within CD8+CD28+ T cell population | 82 | 89 | 94 | 60 | 47 |
% of CD28– cells within CD8+ T cell population | 73 | 67 | 79 | 14 | 85 |
% of CD27– cells within CD8+CD28– T cell population | 86 | 83 | 83 | 40 | 91 |
% of SLAMF7+ cells within CD8+CD28– T cell population | 100 | 99 | 98 | 96 | 99 |
% of CD4+CD8+ DP cells within CD3+ T cell population | 6 | 23 | 13 | 1 | 2 |
% of SLAMF7+ cells within CD4+CD8+ DP T cell population | 98 | 99 | 99 | 22 | 70 |
% of CD56+ cells within CD3+ T cell population | 19 | 26 | 30 | 5 | 18 |
% of SLAMF7+ cells within CD3+CD56+ NKT cell population | 99 | 99 | 99 | 97 | 99 |
CD3+CD56+SLAMF7+ cell count/µl | 206 | 256 | 350 | 40 | 209 |
CD19+ B cell cell count (100–500/µl) | 7 | 8 | 10 | 128 | 1 |
CD3-CD56+ NK cells cell count (90–600/µl) | 101 | 57 | 97 | 150 | 156 |
% of CD56+ cells within CD3– cell population | 8 | 31 | 59 | 52 | 50 |
% of SLAMF7+ cells within CD3–CD56+ NK cell population | 98 | 99 | 98 | 98 | 99 |
CD3–CD56+SLAMF7+ cell count/µl | 7 | 16 | 56 | 77 | 76 |
IgG4-RSM: IgG4-related sclerosing mesenteritis; GPA: granulomatosis with polyangiitis; HD: healthy donor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.